About Bioblast Pharma Ltd
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ORPN
- Previous Close: $1.04
- 50 Day Moving Average: $1.23
- 200 Day Moving Average: $1.45
- 52-Week Range: $0.92 - $7.95
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.42
- P/E Growth: 0.00
- Market Cap: $17.05M
- Outstanding Shares: 16,391,000
- Beta: 0.16
- Return on Equity: -52.90%
- Return on Assets: -46.88%
Companies Related to Bioblast Pharma Ltd:
- Current Ratio: 6.67%
- Quick Ratio: 6.67%
What is Bioblast Pharma Ltd's stock symbol?
Bioblast Pharma Ltd trades on the NASDAQ under the ticker symbol "ORPN."
Where is Bioblast Pharma Ltd's stock going? Where will Bioblast Pharma Ltd's stock price be in 2017?
2 brokers have issued 12-month price objectives for Bioblast Pharma Ltd's stock. Their predictions range from $15.00 to $23.00. On average, they anticipate Bioblast Pharma Ltd's share price to reach $19.00 in the next twelve months.
When will Bioblast Pharma Ltd announce their earnings?
Bioblast Pharma Ltd is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.
Who owns Bioblast Pharma Ltd stock?
Bioblast Pharma Ltd's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.73%).
Who bought Bioblast Pharma Ltd stock? Who is buying Bioblast Pharma Ltd stock?
Bioblast Pharma Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy Bioblast Pharma Ltd stock?
Shares of Bioblast Pharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bioblast Pharma Ltd stock cost?
One share of Bioblast Pharma Ltd stock can currently be purchased for approximately $1.04.